Aptus Pharma Ltd

₹ 345 -1.17%

01 Apr - close price

About

Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.^[1]

Key Points

Business Profile^[1]
Aptus Pharma Limited is a Gujarat-based marketer and distributor of pharmaceutical formulations, operating in an asset-light model through contract manufacturing partners. It offers a diverse portfolio of 194 products across multiple therapeutic categories.

Website BSE

Market Cap ₹ 237 Cr.
Current Price ₹ 345
High / Low ₹ 364 / 80.8
Stock P/E 66.9
Book Value ₹ 31.6
Dividend Yield 0.00 %
ROCE 38.2 %
ROE 70.9 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 61.0%
Company's working capital requirements have reduced from 51.8 days to 36.4 days

Cons

Stock is trading at 10.9 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE SME IPO

Edit Columns

Loading peers table ...

Detailed Comparison with:

Half Yearly Results

Figures in Rs. Crores

	Sep 2024	Sep 2025
	9.76	14.38
	7.78	11.45
Operating Profit	1.98	2.93
OPM %	20.29%	20.38%
	0.00	0.01
Interest	0.11	0.43
Depreciation	0.11	0.16
Profit before tax	1.76	2.35
Tax %	25.57%	25.53%
	1.31	1.75
EPS in Rs	13.10	2.55
Raw PDF

Profit & Loss

Figures in Rs. Crores

	Mar 2023	Mar 2024	Mar 2025
	13.90	17.81	24.56
	13.28	16.27	19.71
Operating Profit	0.62	1.54	4.85
OPM %	4.46%	8.65%	19.75%
	0.00	0.03	0.08
Interest	0.14	0.24	0.47
Depreciation	0.18	0.21	0.27
Profit before tax	0.30	1.12	4.19
Tax %	33.33%	28.57%	26.01%
	0.19	0.80	3.10
EPS in Rs	6.33	26.67	6.20
Dividend Payout %	0.00%	0.00%	0.00%

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	38%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	288%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	61%
Last Year:	71%

Balance Sheet

Figures in Rs. Crores

	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	0.30	0.30	5.00	6.86
Reserves	0.67	1.47	1.97	14.84
	2.22	5.31	10.35	8.13
	3.02	2.95	4.60	9.76
Total Liabilities	6.21	10.03	21.92	39.59
	0.52	0.63	0.99	1.18
CWIP	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00
	5.69	9.40	20.93	38.41
Total Assets	6.21	10.03	21.92	39.59

Cash Flows

Figures in Rs. Crores

	Mar 2023	Mar 2024	Mar 2025
	-0.18	-2.17	-1.84
	-0.35	-0.30	-0.54
	0.81	2.86	6.68
Net Cash Flow	0.28	0.38	4.30
Free Cash Flow	-0.53	-2.50	-2.46
CFO/OP	-10%	-119%	-15%

Ratios

Figures in Rs. Crores

	Mar 2023	Mar 2024	Mar 2025
Debtor Days	63.02	68.66	83.82
Inventory Days	176.00	183.57	285.06
Days Payable	104.07	72.25	52.89
Cash Conversion Cycle	134.95	179.97	315.98
Working Capital Days	51.99	67.02	36.41
ROCE %		26.48%	38.20%

Shareholding Pattern

Numbers in percentages

	Sep 2025	Dec 2025
	72.89%	72.89%
	10.03%	0.00%
	2.80%	0.00%
	14.29%	27.11%
No. of Shareholders	213	302

	Dec 2025
	72.89%
	27.11%
No. of Shareholders	302

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

No data available.

Concalls

Feb 2026

Transcript

AI Summary
PPT